Pipeline


Pipeline (May 2016)
Lead Compound
Design
Drug
Optimization
Preclinical
Efficacy
Preclinical
Toxicity

Phase 1

T12/FST12
Indication: NSCLC
Target: HMW GPBP

GPBP-Mab/FSM26
Indication: IPF
Target:
HMW GPBP

GPBP Inhibitor
Indication: Renal Disease
Target: HMW GPBP

GPBP-Mab/FSM26
Indication: Diabetes
Target:
HMW GPBP

Patents

The company owns a portfolio of 45 issued patents on GPBP-related technologies including GPBP small molecule inhibitors (composition of matter claims issued), GPBP specific monoclonal antibodies, and a broad range of medical uses (method of use claims issued). Composition of matter claims for the Company’s lead drug candidate FST12 are issued in the US, Europe, Japan and China.

Espectometro